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sites, including the lumen ofthe airways, the mucosal cell surface, the 
bronchial tnucosal tissue, epithelial lining fluid and within the 
alveolar macrophages. Antibiotic therapy should be directed to cover 
the key pathogens, but data on antibiotic penetration to these 
infection sites are relevant. Thus an antibiotic used in respiratory tract 
infections should demonstrate good penetration into respiratory 
tissues, as well as potent activity against respiratory pathogens. A long 
terminal half-life allowing once-daily dosing is advantageous because 
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it is convenient for the patient and may therefore aid compliance. 
However, tissue penetration should not be achieved at the expense 
of therapeutic serum concentrations, especially in pneumonia, where 
pneuniococcal infections in particular may be associated with 
bactereiiiia. Treatment of lower respiratory tract infection in the 
community is largely empirical, and the broad-spectrum anti- 
microbial activity, tissue distribution and efticacy and safety profiles 
of fluoroquinolones indicate that they have a place in such infections. 
Aiiiong the new quinolones, grepafloxacin demonstrates excellent 
activity against the important community-acquired respiratory 
pathogens and is highly concentrated in lung tissues, attaining levels 
many times higher than the corresponding serum level and con- 
siderably above the MICW for relevant bacterial pathogens. At the 
same time, daily doses of 400 mg and 600 mg result in serum levels 
above the MICW for key pathogens, including Streptococcirs 
prierrmoniae, and the extended half-life of 12 h allows once-daily 
dosing . 
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Newer fluoroquinolones such as grepafloxacin have denionstrated 
efficacy in the treatment of community-acquired pneumonia and 
acute bacterial exacerbations of chronic bronchitis (ABECB). In a 
recent large community-acquired pneumonia study, 10 days treat- 
ment with grepafloxacin 600 nig once daily was found to be clinically 
and microbiologically equivalent to 10 days of clarithromycin 500 mg 
twice-daily Clinical success rates in patients infected with Streptococcus 
pneurnoniac, Haemoplrilus ir!puenzae or Moraxella cararrkalis were 80% 
in the grepafloxacin group and 73% in the clarithroniycin group (not 
significant). I n  patients infected with atypical pathogens (n=57), 
response rates were 91% in the grepafloxacin-treated group and 82% 
of thow receiving clarithromycin (not significant). 
I n  the prevailing cliinate of limited healthcare resources, the costs 
associated with treatment have become increasingly important. Thus 
shortening or modifying treatnient regimens without loss of efficacy 
could have benefits. In the treatment of ABECB, a 5-day course of 
grepafloxacin 400 mg once-daily has been shown to be clinically as 
effective as 10  days of clarithromycin 500 nig twice-daily At the post- 
treatment assessment, bacteriologic success was higher in patients 
receiving 5 days grepafloxacin than in those receiving 10 days 
clarithromycin, particularly with H .  irq'luenzae (88% versus 56%, 
P<O.OOl) or H .  parair!fluenzae (94% versus 51%, P<0.001). In 
addition, eradication of pathogens from sputum occurred signi- 
ficantly more rapidly in grepafloxacin-treated patients (2 days) than 
in those receiving clarithromycin (6 days) (P<0.001). All treatments 
were well tolerated, with the most conimon adverse events being 
nausea, vomiting and abnormal taste. These data indicate that 
grepafloxacin is a potent antibiotic for the treatment of coniniunity- 
acquired LRTIs, with advantages in pathogen eradication compared 
to clarithrornycin in patients with chronic bronchitis. 
Over the last two decades we have seen an increase in the nunibcr of 
systemic fungal infections, in particular, those due to opportunistic 
systemic pathogens. This is due to an increase in the population of 
imiiiunoconipromised hosts, including those with AIlX. Candida is 
the most conimon systemic fungal pathogen worldwide. Crypto- 
coccosis is now seen rnuch more often because of its high prevalence 
in AIDS patients, and up to 20%) of these patients inay develop it, 
depending on what part of the world they live in. Aspeyilliis is a innjor 
cause of mortality i n  leukemics and in hone iiiarrow and solid organ 
transplantation, and the number of these infections is increasing a$ 
the use of these therapeutic techniques increases. Early diagnosis arid 
treatment of these infectious is essential for an optimal prognoris. 
Diagnosis of opportunist systemic fungal infections is difficult. 
Cryptococcosis and infections caused by diinorphic fungi are 
relatively easy to diagnose, providing the correct tests are done. 
However, difficulty is encountered with the diagnosis of invaqive 
aspergillosis and candidosis. With Candida the occurrence of com- 
mensal yeasts can be confusing, so that the niere isolation of yeasts, 
unless it is froin ,I normally sterile site, means little. C a d i d a  
septicemia is helpful in diagnosing deep seated infection but transient 
candideniia which is of no clinical relevance also occurs. With 
Aspcgillnr there is difficulty in isolating the organism and only less 
than 30% of patients with invasive aspergillosis are positive by culture. 
Serology can play a useful role for some disease but for aspergillosis 
and candidosis the tests lack sensitivity and specificity. Antibody 
testing is giving way to tests for antigens, usually polysacchdride 
antigen, and now commercial kits are available for these tests. 
However, antigen tests lack sensitivity. Testing for fungal metabolites 
has been attempted, particularly for Caridida, but so far this has met 
with only limited s~iccess. The iiiost promising way forward would 
seem to be molecular diagnosis based on PCR testing for fungal 
DNA. There is much current work in this area but the tests 
developed so far are still to be fully evaluated. 
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Molecular diagnosis of fungal infections is needed for several reawn\:  
an increase in the nuniber of patients at risk, of cases, of species of 
yeasts and ftingi involved, of resistant fungi, and ~ l s o  thc limits of 
conventional diagnostic approaches. Broad spectrum or restricted to 
a single species, genoinic amplification methods such as PCR con-  
prise the following steps: DNA extraction, selection of primers, 
amplification protocols, detection of amplification products, vnlida- 
tion, and clinical studies. Extraction offungal DNA IS generally iiiore 
difficult than bacterial DNA. Target for priiners ideally should be 
present in multiple copies (such as ribosomal or mitochondria1 
targets). They can be either genus (Cawdido, Aspetgillus), or species 
(C. albicans, C. krnsri), specific or broad raiige (pan fungal), followed 
by REA or probing of the amplification product. Careful validation 
ofthe molecular test in a clinical setting is important. These last yem, 
two main problems have been addressed: the molecular diagnosis of 
invasive candidiasis in blood or normally sterile fluids, and of invasive 
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aspergillosis (IA) in BAL, serum or blood. For Candida, several 
procedures have given at best a sensitivity equal to that of blood 
culture, but in a shorter period of time. No extensive prospective 
studies have yet been completed. For IA, again several amplification 
tests have been developed, but none has allowed to anticipate 
diagnosis of IA compared to the combination of clinical, radiological, 
and immunological signs and results. Rapid molecular identification 
of yeast and fungi, either directly or from an already positive culture 
(blood culture for example), can be very useful to direct therapy. In 
situ PCR applied to biopsy material would also give a definitive 
diagnosis, particularly in cases where conventional cultures stay 
negative. In the near future, molecular tests to detect determinants of 
resistance to antifungal drugs, follow response to treatment, and 
measure virulence factors to differentiate a true infection from a 
colonization, will be of considerable help to the clinicians. 
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In recent years, a national survey of nosocomial fungal infections in 
American hospitals has shown a two-fold increase in the incidence 
of these infections from 1980 to 1990. Similar results have been 
reported in Europe, with one large autopsy study in a miscellaneous 
patient population showing an increase in the prevalence of autopsy- 
detected invasive fungal infections from 2.2% between 1978 and 1982 
to 5.1% in recent years. Finally, a recently completed surveillance 
study of bloodstream infections in children with cancer conducted 
by the Italian Association for Pediatric Hematology and Oncology 
found a 10% incidence of fungemia among all bloodstream infec- 
tions. Between 1988 and 1992, the MD Anderson Cancer Center in 
Houston observed a significant decrease in incidence of candidemia, 
with a relative increase of Candida krusei and C. glabrata infections and 
a decrease of C. albicans and C. tropicalis. The Invasive Fungal 
Infection Group of the EORTC conducted a surveillance study of 
candidemia within 30 centers. Of the 249 documented episodes of 
candidemia, non-albicans candidemia accounted for 30% in patients 
with solid tumors and for 64% in those with hematologic malig- 
nancies (P less than 0.001). Antifungal prophylaxis and underlying 
disease were the most important factors associated with the emer- 
gence of non-albicans species. The 30-day overall mortality rate was 
39%, the risk of which was mainly associated with increasing age, 
advanced underlying disease, intensive chemotherapy, shock, lack of 
antifungal prophylaxis, and C. glabrata or C. tropicalis infections. Fungal 
infection-related mortality in cancer patients can be very high. For 
example, among 124 patients who underwent bone marrow trans- 
plantation from an unrelated donor at Fred Hutchinson Cancer 
Research Center in Seattle, 14 (1 1%) developed aspergillosis within 
100 days of their transplant, and 11 (79%) ofthese subsequently died. 
Among other emerging yeasts, it is worth mentioning Triclzosporori 
spp. and Rhodotomla spp. Among filamentous fungi, agents of hyalo- 
hyphomycosis and phaeohyphomycosis are also increasingly reported. 
Infections caused by these agents are very difficult and sometimes 
impossible to treat, unless recovery of the underlying immuno- 
deficiency is rapidly achieved. 
1x1 Clinical pharmacokinetics of a new azole- 
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Voriconazole is a broad-spectrum azole antifungal agent which is 
currently in phase I11 clinical trials for the treatment of serious 
systemic fungal infection. It is available as formulations for oral and 
intravenous administration. Following oral administration, voricon- 
azole is well absorbed with a mean time to maximum plasma 
concentration of 1-2 h post-dose and bioavailability greater than 
80%. Multiple dosing in the presence of food reduces systemic 
exposure by 22% compared with the fasted state. Therefore, voricon- 
azole should not be administered within 1 h of food intake. 
Voriconazole exhibits non-linear pharmacokinetics. Multiple dosing 
at intravenous doses of 3 mg/kg b i d .  and oral doses of 200 mg b.i.d. 
result in a mean accumulation of approximately threefold and a 
maximum accumulation offivefold which is not premctable from the 
single-dose data. Voriconazole has a mean terminal-phase half-life of 
about 6 h. Steady state, for both intravenous and oral dosing, is 
achieved within 6 days. Use of a loading dose (6 mg/kg b.i.d. X 1 day) 
results in steady-state plasma concentrations being achieved by the 
third day of dosing. Voriconazole is widely dntribnted throughout 
body fluids with a volume of distribution of about 2 L/kg. It is 
extensively metabolized to one major and several minor metabolites. 
The elimination of voriconazole occurs primarily by metabolic 
clearance. In vitro studies using human liver microsomes have 
demonstrated that voriconazole is metabolized by cytochrome P-450 
isozymes CYP2C9, CYP3A4 and CYP2C19. It may inhibit the 
activity of CYP2C9, CYP2C19 and, to a lesser extent, CYP3A4. 
Potential drug interactions with voriconazole will be reviewed. 
1x1 Advances in the treatment of oral and 
esophageal candidiasis 
M. Ruhnke. CharitC Campus Virchow-Klinikum, Abt. Innere Medizin, 
Berlin, Germany 
Oropharyngeal candidiasis (OPC) occurs in as many as 80% of HIV- 
positive patients at some point during the course of HIV hsease. The 
mean incidence of esophageal candidiasis (OEC) among HIV- 
positive patients is reported to range tiom 10% to 20%. Esophageal 
candidiasis is the first opportunistic infection in 5-10% of HIV- 
infected patients and is considered to be the second most common 
AIDS-defining illness after Pneumocystis carinii pneumonia. Candida 
albicans is the most common cause of OPC and OEC, accounting for 
most cases, but other species, including C. tropicalis, C .  glabrata, and 
C. kmnrmei, have been reported. Initiation of therapy is ofien empirical 
and is guided by the clinical presentation of the patient. Topical 
therapy with antifungal agents, including nystatin, amphotericin B 
suspension or clotrimazole troches (only in the USA), is useful in 
OPC but often unsuccessful in OEC for various reasons. Today, the 
triazole agents fluconazole and itraconazole are the first-line treat- 
ment for OPC and OEC in most centers. Both agents are generally 
safe and well tolerated and produce a rapid clinical response. They 
may be given either topically as a suspension or orally as capsules and 
have systemic antifungal activity against C. albicans and other yeast 
infections. However, certain Candida species are intrinsically highly 
resistant (e.g. C. krusei) to fluconazole, and the emergence of 
fluconazole-resistant strains of C. albicans has been reported during 
therapy. Resistance to itraconazole similar to that observed with 
fluconazole has not been frequently reported. The occurrence of 
cross-resistance between azoles in vitro is often reported, but these 
findings should be interpreted in light of both clinical and micro- 
biological data. Newer very promising agents, either triazole deriva- 
tives (e.g. voriconazole, SCH56592) or echinocandins (e.g. 
LY303366, MK-0991) have been developed and are currently being 
evaluated in clinical and microbiological studies for fluconazole- 
resistant candida infections. 
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Disseminated fungal infections have become a major factor in the 
prognosis of patients with compromised immunity. In spite of toxi- 
city, amphotericin €3 is the antifungal agent of choice for disseminated 
iiiycotes. Flucoiiazole offers no protection against aspergillosis, 
whereas itraconazole, in doses of more than 400 mg/day, has docu- 
mented in vivo activity against most Candida and .4speqqillirs species. 
ac well as a wide array of other fungal pathogens. The new 
cyclodextriii-based oral solution and intravenous preparation show 
improved absorption, but compliance appears to be limited. Trans- 
plant recipients on cyclosporin require an immediate dose reduction 
followed by frequent monitoring. Starting treatment with intra- 
venous amphotericin B followed by oral itraconazole appears to be a 
feasible and effective approach. Voriconazole is a new, oral and 
intravenous triazole derivative with a broad spectrum of antifungal 
activity, including Aspergillus. In guinea pigs, voriconazole was 
superior to itraconazole and amphotericin B against jim@tus. 
After oral administration in human volunteers, a t,,,,, of less than 2 h 
and a f2 of 6 h have been observed. In non-neutropenic patients with 
chronic aspergillosis, 50% of whom had failed therapy with 
itraconazole or amphotericin B, 11/19 (58%) patients responded 
favorably to voricoiiazole (200 mg PO b.i.d.). In acute invasive 
aspergillosis in neutropenic hosts, a 6 nig/kg q l2  h IV dose of 
voriconazole was given for 1 day, followed by 3 mg/kg q12 h IV until 
the patient could take 200 mg PO b.i.d. This study comprised 141 
cases ofwhom 102 were assessable; 17% showed a complete response, 
36% a partial response, 2O%I a stable disease and 27% a failure. A 
survival rate of 58% was encountered among bone marrow transplant 
recipients. Around 8% of patients experienced transient visual 
disturbances. 
Clinical microbiology: a pivotal interface in 
patient and health care management 
m] Pre-laboratory specimen management: the first 
interface 
H. <k i s s .  HyXieric Instirut, Heidelbey, Germany 
Spiraling costs in the healthcare environment have obliged many 
medical microbiology laboratories to focus on cost-saving with the 
consequences of downsizing, outsourcing and the creation of cen- 
tralized laboratory facilities far away from the patients. Many 
clinicians and administrators are unaware that this development 
increases the risk ofproducing clinically irrelevant data, which in turn 
will have a significant negative impact on patient outcome and cost- 
effective healthcare delivery However, these circumstances are also to 
be blamed on microbiologists who too often have focused exclusively 
on laboratory workflow and diagnostic procedures, while neglecting 
the significance of the pre-analytic steps, including specimen 
selection, collection and transport. This ‘garbage-in-garbage-out’ 
situation produces laboratory data which may lead not only to 
misdiagnosis, extended length of stay, or inappropriate therapy, but 
also to important cost factors. It is well known that, often, specimens 
of the least clinical value require the most laboratory resources. 
Nothing is more important to the effectiveness of a laboratory than 
a specimen that has been appropriately selected, collected, and 
transported. 
Improvements in the early steps of the ‘total niicrobiology testing 
process’ include the following: including specimen nianagement in 
the curricula of medical and nursing schools; opening the black box 
‘micro-lab’ and making analytic procedures comprehensible and 
understandable; demonstrating the significance of expeditious trans- 
portation from patient bed to the laboratory; improving specimen 
collection material and transport media to inaintain ypecinien 
integrity 
Efficient specimen processing and data 
generation 
W. Goessens. Erasrnns I.irriwrsity Mfdical Ceitter, Roftcrdom, 
The h d r c r l a n d s  
Ongoing changes I n  infectiou, disease pathogens, patient populations 
and presentations of infectious diseases have increased the need for 
the rapid and accurate assessment of microbiological data. The 
speeding-up of the analytic process in the clinical microbiology 
laboratory should be adapted at several levels in order to tignificantly 
affect patient care. First. the analytic processes should be organized as 
efficiently as possible. Microbiological data are often obtained in a 
sequential order. This natural day-to-day rhythm can be changed by 
the introduction ofa change in working hours so that initial findings 
can be confirnied within one and the same working day instead of 
on the following day. Second, to be able to anticipate, relevant 
specimens and/or patient categories should bc monitored throughout 
the whole process ,of analysis. This can be achieved, for instance, by 
labeling of special patient categories, or by the analysis of their 
specimens by a dedicated technician, or by creating a special bench. 
Protocollation of analysis procedures and continuous education of 
technicians result In early recognition of significant pathogens or 
multiresistant organisms. The third level is to shorten the analysis 
process by applying new techniques or instruments. Replacing classic 
growth-based techniques by new and rapid instant techniques will 
not always automatically lead to a change in clinical decision-making. 
The correct impleinentation rather than the techniques themselves 
will be discussed. The speeding-up of the analytic process is only 
fruitful if the relevant information generated arrives earlier at the 
bedside of the pati,-nt without a delay of hours, or even days. This 
should be enabled by making use ofpresent information technologies 
by creating a laboratory information system which supports and 
facilitates laboratory workflow and ensures the reporting and/or 
summarizing of prdiminary or final results throughout the day. 
Sensing and responsiveness 
V Jarlier. Hopital P;fiC-SalpetriBre, Paris, France 
The laboratory of clinical microbiology plays a pivotal role in each 
medical institution by sensing the important medical and epideinio- 
logic events and developing feedback at patient and institution levels. 
The laboratory is a critical place to process and analyze the relevant 
microbiological data, and to integrate them with data from other 
sources in order to construct a vigilance system able to detect and 
report uncommon or abnormal events on the basis of quantitative or 
qualitative information. The laboratory should develop responses to 
patient and hospital context by (1) adapting workflows/techniques to 
new situations, (2) anticipating and performing additional investi- 
gations at paticnt or environmental lcvcls (e.g. search for MDK 
carriers among contact patients), ( 3 )  providing a basis ( e g  rpidemio- 
logic curve for MDR) for counseling, action and intervention. 
The prerequisites for meeting these priorities are both technical 
and managerial: the laboratory information system (LIS) should 
